As of 11-2-2018 the FDA conditionally approved Loralatinib. It’s brand name is Lorbrena.
The approval is for Loralatinib treatment for patients who have already received either: 1) crizotinib and one other ALK inhibitor, or 2) as first line treatment only either: A) Alectinib, or B) Ceritinib.
At this time Brigatinib as a first line treatment has not been approved by The FDA. Although a positive Phase 3 trial results were recently published.
The FDA approval is conditioned on a Phase 3 trial being completed.